Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) Long-Term Debt Issuances (2022 - 2024)

Tarsus Pharmaceuticals has reported Long-Term Debt Issuances over the past 3 years, most recently at $75.0 million for Q2 2024.

  • Quarterly results put Long-Term Debt Issuances at $75.0 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Sep 2025 was $75.0 million (changed 0.0% YoY), and the annual figure for FY2024 was $75.0 million, up 650.0%.
  • Long-Term Debt Issuances for Q2 2024 was $75.0 million at Tarsus Pharmaceuticals, up from $5.0 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for TARS hit a ceiling of $75.0 million in Q2 2024 and a floor of $5.0 million in Q1 2023.
  • Median Long-Term Debt Issuances over the past 3 years was $12.5 million (2022), compared with a mean of $26.2 million.
  • Peak annual rise in Long-Term Debt Issuances hit 75.0% in 2023, while the deepest fall reached 75.0% in 2023.
  • Tarsus Pharmaceuticals' Long-Term Debt Issuances stood at $20.0 million in 2022, then crashed by 75.0% to $5.0 million in 2023, then skyrocketed by 1400.0% to $75.0 million in 2024.
  • The last three reported values for Long-Term Debt Issuances were $75.0 million (Q2 2024), $5.0 million (Q3 2023), and $5.0 million (Q1 2023) per Business Quant data.